Clinical Trials Browser

Lung Diseases, Interstitial

NCT07416058 2026-02-17

PHOENIX

Phase 2 Not yet recruiting

61 enrolled

Thoracic

Diabetes Mellitus, Insulin-Dependent, 12, Adenocarcinoma of Lung

NCT07405190 2026-02-12

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

Phase 2 Not yet recruiting

46 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07234058 2026-02-11

LAG-MAPS

Phase 2 Not yet recruiting

126 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT07229339 2026-02-05

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Phase 2 Not yet recruiting

16 enrolled

Lung Non-Squamous Non-Small Cell Carcinoma

NCT07365410 2026-01-26

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Phase 2 Not yet recruiting

60 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT07309952 2025-12-30

SACTION 2501

Phase 2 Not yet recruiting

28 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07274384 2025-12-10

HYPERBOLIC

Phase 2 Not yet recruiting

74 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

NCT06944470 2025-04-25

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

Phase 2 Not yet recruiting

76 enrolled

Thoracic

NSCLC

NCT06890182 2025-03-21

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

Phase 2 Not yet recruiting

31 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06861218 2025-03-06

Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

Phase 2 Not yet recruiting

42 enrolled

CNS

Meningeal Carcinomatosis

NCT06746870 2024-12-24

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

Phase 2 Not yet recruiting

148 enrolled

BreastThoracic

NSCLC

NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

430 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06688656 2024-11-14

Peri-E

Phase 2 Not yet recruiting

30 enrolled

Thoracic

Lung Neoplasms

NCT06649448 2024-10-18

EF-001

Phase NA Not yet recruiting

200 enrolled

Other solid neoplasm

Solid Tumor Cancer

NCT06497543 2024-09-19

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

Phase 2 Not yet recruiting

80 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

Phase 2 Not yet recruiting

178 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06045767 2024-06-03

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

Phase 2 Not yet recruiting

30 enrolled

Thoracic

Non-small Cell Lung Cancer Metastatic

NCT06391008 2024-04-30

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

44 enrolled

Thoracic

Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer

NCT06109402 2023-12-19

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

160 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06142617 2023-11-21

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Phase 2 Not yet recruiting

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05891080 2023-06-06

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Phase 2 Not yet recruiting

124 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05132985 2021-12-10

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

Phase 2 Not yet recruiting

45 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04772287 2021-02-26

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Phase 3 Not yet recruiting

341 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04153734 2019-11-06

Evolution

Phase 2 Not yet recruiting

21 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

PHOENIX

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

LAG-MAPS

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

SACTION 2501

HYPERBOLIC

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Peri-E

EF-001

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer

Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Evolution